In addition, nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1), also showed a survival benefit compared with placebo in patients with advanced gastric cancer refractory to two or more previous regimens of chemotherapy [6], and more recently, trifluridine/tipiracil, a novel oral combination cytotoxic drug also known as TAS-102, has significantly improved overall survival (OS) compared with placebo in heavily pretreated population of patients with advanced gastric cancer [7]. This evidence concerns the gene PDCD1 and gastric cancer.